HRP20220972T1 - Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu - Google Patents
Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu Download PDFInfo
- Publication number
- HRP20220972T1 HRP20220972T1 HRP20220972TT HRP20220972T HRP20220972T1 HR P20220972 T1 HRP20220972 T1 HR P20220972T1 HR P20220972T T HRP20220972T T HR P20220972TT HR P20220972 T HRP20220972 T HR P20220972T HR P20220972 T1 HRP20220972 T1 HR P20220972T1
- Authority
- HR
- Croatia
- Prior art keywords
- ophthalmic preparation
- less
- months
- mass
- ophthalmic
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title claims 5
- 239000003149 muscarinic antagonist Substances 0.000 title claims 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 239000006172 buffering agent Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 claims 2
- QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004423 myopia development Effects 0.000 claims 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 229930003347 Atropine Natural products 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229920002413 Polyhexanide Polymers 0.000 claims 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960000396 atropine Drugs 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960002028 atropine sulfate Drugs 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 150000001642 boronic acid derivatives Chemical class 0.000 claims 1
- 229960003431 cetrimonium Drugs 0.000 claims 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 229940054534 ophthalmic solution Drugs 0.000 claims 1
- 239000002997 ophthalmic solution Substances 0.000 claims 1
- 125000005430 oxychloro group Chemical group 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 230000004515 progressive myopia Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229960001922 sodium perborate Drugs 0.000 claims 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (18)
1. Oftalmološki pripravak, naznačen time, da sadrži muskarinski antagonist i deuteriranu vodu od 0,001% po masi do 0,05% po masi, na pD vrijednosti od 4,2 do 7,9, pri čemu muskarinski antagonist je atropin ili atropin sulfat.
2. Oftalmološki pripravak prema patentnom zahtjevu 1, naznačen time, da oftalmološki pripravak ima jednu od sljedećih pD vrijednosti: manje od 7,3, manje od 7,2, manje od 7,1, manje od 7, manje od 6,8, manje od 6,5, manje od 6,4, manje od 6,3, manje od 6,2, manje od 6,1, manje od 6, manje od 5,9, manje od 5,8, manje od 5,2, ili manje od 4,8 nakon produljenog vremenskog perioda pod skladišnim uvjetima.
3. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time, da oftalmološki pripravak ima jedan od sljedećih: najmanje 80%, najmanje 85%, najmanje 90%, najmanje 93%, najmanje 95%, najmanje 97%, najmanje 98%, ili najmanje 99% muskarinskog antagonista na temelju inicijalne koncentracije nakon produljenog vremenskog perioda pod skladišnim uvjetima.
4. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da oftalmološki pripravak nadalje ima potentnost kao jednu od sljedećih: najmanje 80%, najmanje 85%, najmanje 90%, najmanje 93%, najmanje 95%, najmanje 97%, najmanje 98%, ili najmanje 99% nakon produljenog vremenskog perioda pod skladišnim uvjetima.
5. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da je produljeni vremenski period jedan od sljedećih: 1 tjedan, 2 tjedna, 3 tjedna, 1 mjesec, 2 mjeseca, 3 mjeseca, 4 mjeseca, 5 mjeseci, 6 mjeseci, 8 mjeseci, 10 mjeseci, 12 mjeseci, 18 mjeseci, 24 mjeseca, 36 mjeseci, 4 godine, ili 5 godina.
6. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da skladišni uvjeti imaju temperaturu skladištenja od 2°C do 10°C ili od 16°C do 26°C.
7. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da se muskarinski antagonist nalazi u pripravku s koncentracijom koja je jedna od sljedećih: od 0,001% po masi do 0,03% po masi, od 0,001% po masi do 0,025% po masi, od 0,001% po masi do 0,02% po masi, od 0,001% po masi do 0,01% po masi, od 0,001% po masi do 0,008% po masi, ili od 0,001% po masi do 0,005% po masi.
8. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da oftalmološki pripravak nadalje sadrži: sredstvo za podešavanje osmolarnosti, poželjno natrijev klorid; konzervans, poželjno odabran od benzalkonij klorida, cetrimonija, natrijevog perborata, stabiliziranog oksikloro kompleksa, SofZia, polikvaternija-1, klorobutanola, edetat dinatrija, poliheksametilen bigvanida, ili njihovih kombinacija; puferski agens, poželjno odabran od borata, kompleksa borat-poliol, fosfatnih puferskih agensa, citratnih puferskih agensa, acetatnih puferskih agensa, karbonatnih puferskih agensa, organskih puferskih agensa, aminokiselinskih puferskih agensa, ili njihovih kombinacija; sredstvo za podešavanje toničnosti; ili njihove kombinacije.
9. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da je oftalmološki pripravak uglavnom oslobođen od prokaina i benaktizina, ili njihovih farmaceutski prihvatljivih soli.
10. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da oftalmološki pripravak nadalje sadrži sredstvo za podešavanje pD vrijednosti, koje se bira od deuterirane klorovodične kiseline (DCl), deuteriranog natrijevog hidroksida (NaOD), deuterirane octene kiseline (CD3COOD), i deuterirane limunske kiseline (C6D8O7).
11. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da oftalmološki pripravak nadalje sadrži sredstvo za podešavanje pH vrijednosti, koje se bira od HCl, NaOH, CH3COOH, i C6H8O7.
12. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da oftalmološki pripravak sadrži jedno od sljedećih: manje od 5% H2O, manje od 4% H2O, manje od 3% H2O, manje od 2% H2O, manje od 1% H2O, manje od 0,5% H2O, manje od 0,1% H2O, ili 0% H2O.
13. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da oftalmološki pripravak nije formuliran kao formulacija koja se može dati injekcijom.
14. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da je oftalmološki pripravak formuliran kao oftalmološka otopina za liječenje oftalmološkog poremećaja koji se bira od predmiopije, miopije, ili progresije miopije.
15. Oftalmološki pripravak prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da je za uporabu u postupku zaustavljanja razvoja miopije ili sprečavanja razvoja miopije, pri čemu postupak obuhvaća primjenu učinkovite količine navedenog oftalmološkog pripravka u oko pojedinca kojemu je to potrebno.
16. Oftalmološki pripravak za uporabu prema patentnom zahtjevu 15, naznačen time, da se oftalmološki pripravak prije prve uporabe skladišti između 2°C i 10°C.
17. Oftalmološki pripravak za uporabu prema patentnom zahtjevu 15, naznačen time, da se oftalmološki pripravak nakon prve uporabe skladišti između 16°C i 26°C.
18. Oftalmološki pripravak za uporabu prema patentnom zahtjevu 15, naznačen time, da je za uporabu u postupku smanjivanja stupnja pojačanja miopije.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016502P | 2014-06-24 | 2014-06-24 | |
| US201462096433P | 2014-12-23 | 2014-12-23 | |
| US201562151926P | 2015-04-23 | 2015-04-23 | |
| US14/726,139 US9421199B2 (en) | 2014-06-24 | 2015-05-29 | Ophthalmic composition |
| PCT/US2015/037249 WO2015200361A1 (en) | 2014-06-24 | 2015-06-23 | Ophthalmic composition |
| EP15811865.3A EP3160471B1 (en) | 2014-06-24 | 2015-06-23 | Ophthalmic compositions comprising a muscarinic antagonist and deuterated water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220972T1 true HRP20220972T1 (hr) | 2022-11-25 |
Family
ID=54868660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220972TT HRP20220972T1 (hr) | 2014-06-24 | 2015-06-23 | Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu |
Country Status (20)
| Country | Link |
|---|---|
| US (11) | US9421199B2 (hr) |
| EP (3) | EP3689350A1 (hr) |
| JP (4) | JP6678362B2 (hr) |
| KR (4) | KR102506109B1 (hr) |
| CN (3) | CN110638749A (hr) |
| BR (1) | BR112016030368B1 (hr) |
| CA (1) | CA2953363C (hr) |
| DK (1) | DK3160471T3 (hr) |
| ES (1) | ES2924243T3 (hr) |
| HR (1) | HRP20220972T1 (hr) |
| HU (1) | HUE059521T2 (hr) |
| IL (1) | IL249643B (hr) |
| LT (1) | LT3160471T (hr) |
| PL (1) | PL3160471T3 (hr) |
| PT (1) | PT3160471T (hr) |
| RS (1) | RS63486B1 (hr) |
| SG (3) | SG10201913976SA (hr) |
| SI (1) | SI3160471T1 (hr) |
| TW (2) | TWI763620B (hr) |
| WO (1) | WO2015200361A1 (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX361858B (es) | 2012-08-24 | 2018-12-18 | Sun Pharma Global Fze | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
| CN107847432A (zh) * | 2015-05-29 | 2018-03-27 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| DK3373976T3 (da) | 2015-11-10 | 2024-04-02 | Sun Pharmaceutical Ind Ltd | Topiske formuleringer og anvendelser deraf |
| RU2747455C2 (ru) | 2016-02-29 | 2021-05-05 | Сан Фарма Глобал Фзе | Циклоспорин-содержащие лекарственные формы для наружного применения и их применения |
| CA3019178A1 (en) * | 2016-04-11 | 2017-10-19 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| ES2929368T3 (es) * | 2016-05-25 | 2022-11-28 | Singapore Health Serv Pte Ltd | Composición acuosa que contiene atropina |
| NZ756936A (en) * | 2017-02-21 | 2022-11-25 | Singapore Health Serv Pte Ltd | Composition and method for preventing or delaying onset of myopia comprising atropine |
| US11642350B2 (en) * | 2017-03-23 | 2023-05-09 | Singapore Health Services Pte Ltd | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |
| PL3600456T3 (pl) | 2017-03-27 | 2024-02-26 | Regeneron Pharmaceuticals, Inc. | Sposób sterylizacji |
| SG11201910085UA (en) | 2017-05-11 | 2019-11-28 | Nevakar Inc | Atropine pharmaceutical compositions |
| US11938056B2 (en) | 2017-06-10 | 2024-03-26 | Eyenovia, Inc. | Methods and devices for handling a fluid and delivering the fluid to the eye |
| AU2018304450B2 (en) * | 2017-07-20 | 2024-05-16 | Seinda Pharmaceutical Guangzhou Corporation | Composition and methods for the treatment of myopia |
| MX2020005217A (es) * | 2017-11-21 | 2020-11-24 | Sydnexis Inc | Composicion oftalmica y dispositivo de administracion de la misma. |
| US11524032B2 (en) | 2018-01-05 | 2022-12-13 | University Of Utah Research Foundation | Treatment of myopic progression |
| CN109157503B (zh) * | 2018-09-25 | 2019-08-16 | 沈阳兴齐眼药股份有限公司 | 防治nitm的药物组合物及其医药用途 |
| CN110934816B (zh) * | 2018-09-25 | 2022-04-08 | 沈阳兴齐眼科医院有限公司 | 一种提高低浓度阿托品眼用制剂稳定性的方法 |
| PT3701938T (pt) | 2019-03-01 | 2024-01-31 | Medivis S R L | Formulações oftálmicas à base de atropina |
| WO2020219707A1 (en) * | 2019-04-24 | 2020-10-29 | Allergan, Inc. | Compositions and methods for treatment of ocular conditions |
| KR102308566B1 (ko) * | 2019-05-28 | 2021-10-05 | 서울대학교병원 | 녹내장 안약의 약물이상반응 진단 키트 |
| CA3146848A1 (en) * | 2019-07-11 | 2021-01-14 | University Of Utah Research Foundation | Multi-agent ocular formulations and treatment methods |
| US20220411482A1 (en) * | 2019-11-15 | 2022-12-29 | Silk Technologies, Ltd. | Stable formulations of silk-derived protein |
| IL293859A (en) * | 2019-12-16 | 2022-08-01 | Sydnexis Inc | Ophthalmic preparations that include d2o |
| CN111821259A (zh) * | 2020-07-14 | 2020-10-27 | 艾尔健康眼药(辽宁)有限公司 | 一种眼用药物组合物 |
| US11850249B2 (en) | 2020-10-05 | 2023-12-26 | Somerset Therapeutics, Llc | Methods of efficiently reducing intraocular pressure |
| KR102245533B1 (ko) * | 2020-11-02 | 2021-04-28 | 주식회사 지게차코리아 | 운송수단용 림 및 이의 제조방법 |
| CA3210064A1 (en) * | 2021-01-28 | 2022-08-04 | Glaukos Corporation | Formulations |
| US20240139166A1 (en) * | 2021-02-04 | 2024-05-02 | Sydnexis, Inc. | Ophthalmic compositions for presbyopia |
| WO2022172089A1 (en) * | 2021-02-12 | 2022-08-18 | I Optima Ltd. | Compound, method and system for ophthalmic surgery |
| CA3211874A1 (en) * | 2021-03-16 | 2022-09-22 | Kumaresh Soppimath | Multi-dose container for ophthalmic compositions |
| EP4088713A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| EP4088714A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| EP4426353A2 (en) * | 2021-11-05 | 2024-09-11 | Calm Water Therapeutics LLC | Methods for using bioadhesive and steric interactions of copolymers to minimize adverse effects |
| US20230277521A1 (en) * | 2022-03-07 | 2023-09-07 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| WO2023172240A1 (en) * | 2022-03-07 | 2023-09-14 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| WO2023171989A1 (ko) * | 2022-03-11 | 2023-09-14 | 주식회사 메디치바이오 | 안질환 예방 또는 치료용 약학 조성물 |
| WO2023215407A2 (en) * | 2022-05-03 | 2023-11-09 | Iview Therapeutics, Inc. | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases |
| US20240033260A1 (en) * | 2022-07-26 | 2024-02-01 | The Chinese University Of Hong Kong | Low-concentration atropine for myopia prevention (lamp-2) study |
| WO2024091789A1 (en) * | 2022-10-26 | 2024-05-02 | Vyluma Inc. | Childhood atropine for myopia progression |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382124B1 (en) | 1958-07-18 | 1994-10-04 | Rohm & Haas | Process for preparing macroreticular resins, copolymers and products of said process |
| NL284933A (hr) | 1961-10-31 | |||
| DE1518819B1 (de) | 1965-04-03 | 1969-12-04 | Basf Ag | Loesungsvermittler fuer pharmazeutische Zwecke |
| SE352811B (hr) | 1971-06-04 | 1973-01-15 | Pharmacia Ab | |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4255415A (en) * | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| US4952586A (en) | 1982-08-27 | 1990-08-28 | The Regents Of The University Of California | Edrophonium-atropine composition and therapeutic uses thereof |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| DE3622399A1 (de) | 1986-07-01 | 1988-02-04 | Eberhardt Schlueter | Selbsttaetige injektionsvorrichtung sowie ampulle oder patrone fuer eine injektionsvorrichtung |
| US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
| US4852582A (en) | 1987-09-11 | 1989-08-01 | Pell Donald M | Method and kit for measuring the effectiveness of bronchodilators |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| IL85312A (en) | 1988-02-03 | 1991-08-16 | Israel State | Injectable pharmaceutical compositions having improved stability |
| JP2617508B2 (ja) * | 1988-02-05 | 1997-06-04 | エーザイ株式会社 | 安定なジフェンヒドラミン含有水溶液 |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| FR2638428B1 (fr) | 1988-10-28 | 1990-12-28 | Transphyto Sa | Conditionnement pour liquides a epurer |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
| US5259998A (en) | 1991-10-04 | 1993-11-09 | Chiron Ophthalmics, Inc. | Method for casting dissolvable ophthalmic shields in a mold |
| US5492689A (en) | 1991-11-19 | 1996-02-20 | The Center For Innovative Technology | Combined virustatic antimediator (COVAM) treatment of common colds |
| US5716952A (en) | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| US5505953A (en) | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5260000A (en) | 1992-08-03 | 1993-11-09 | Bausch & Lomb Incorporated | Process for making silicone containing hydrogel lenses |
| FR2702660B1 (fr) | 1993-03-17 | 1995-05-24 | Karl Simpson | Compositions thérapeutiques stabilisées et leur procédé de préparation. |
| US5840770A (en) | 1993-08-24 | 1998-11-24 | Hill Medical Corporation | Method of killing tumor cells |
| US5490938A (en) | 1993-12-20 | 1996-02-13 | Biopolymerix, Inc. | Liquid dispenser for sterile solutions |
| ATE317690T1 (de) | 1994-04-08 | 2006-03-15 | Qlt Usa Inc | Flüssige zusammensetzungen zur arzneistoffabgabe |
| GB2293100A (en) | 1994-09-15 | 1996-03-20 | Medeva Europ Ltd | Pharmaceutical compositions with deuterium oxide |
| CZ285636B6 (cs) | 1995-02-07 | 1999-10-13 | Ústav Makromolekulární Chemie Av Čr | Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby |
| WO1997016192A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| FR2742357B1 (fr) | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| US5900360A (en) | 1996-04-10 | 1999-05-04 | Welch; William J. | Correction of genetic defects using chemical chaperones |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US20030157187A1 (en) | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
| US20040136915A1 (en) | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
| FR2770843B1 (fr) | 1997-11-13 | 2000-01-14 | Lavipharm Lab | Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications |
| US6149670A (en) | 1999-03-11 | 2000-11-21 | Alsius Corporation | Method and system for treating cardiac arrest using hypothermia |
| US5976499A (en) | 1998-09-04 | 1999-11-02 | Johns Hopkins University | Macroscopic sweat test for cystic fibrosis |
| IN185228B (hr) | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
| WO2000069470A2 (en) | 1999-05-17 | 2000-11-23 | Aesgen, Inc. | Improved cellular uptake of bioactive agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| CN1323595A (zh) | 2000-05-11 | 2001-11-28 | 朱卫国 | 用于青光眼的药物组合物 |
| US20050251254A1 (en) | 2000-06-02 | 2005-11-10 | Brady Daniel G | Method of implanting accommodating intraocular lenses |
| US20030195179A1 (en) | 2000-08-25 | 2003-10-16 | Shirou Sawa | Aqueous suspension preparations |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| CN1509172A (zh) | 2001-05-25 | 2004-06-30 | ά����ҩ��˾ | 哌仑西平眼用凝胶剂 |
| CN1206988C (zh) | 2002-05-10 | 2005-06-22 | 刘继东 | 硫酸阿托品眼用凝胶 |
| CA2535846A1 (en) | 2003-08-15 | 2005-02-24 | Qlt Usa, Inc. | Adhesive bioerodible transmucosal drug delivery system |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| WO2005072656A1 (en) | 2004-01-27 | 2005-08-11 | Osteotech, Inc. | Stabilized bone graft |
| US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US7659260B2 (en) | 2005-01-14 | 2010-02-09 | Eddie Francis Kadrmas | Tamponade compositions and methods for retinal repair |
| US9238003B2 (en) | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
| CA2597219C (en) | 2005-02-04 | 2014-04-15 | Auburn University | Contact drug delivery system |
| CN1939534B (zh) | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
| GB2423711B (en) * | 2005-10-24 | 2007-02-14 | Fortune Apex Dev Ltd | Method for preparing a pharmaceutical composition with enhanced mucoadhesion |
| US20100022495A1 (en) | 2005-11-01 | 2010-01-28 | President And Fellows Of Harvard College | Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis |
| US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| CN101049287A (zh) * | 2006-04-07 | 2007-10-10 | 财团法人长庚纪念医院 | 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法 |
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| JP2007308398A (ja) * | 2006-05-17 | 2007-11-29 | Chang Gung Memorial Hospital | 目薬、及びその製造方法 |
| US7691099B2 (en) | 2006-07-12 | 2010-04-06 | Ntk Enterprises, Inc. | Deuterated ocular solutions for LTK and other surgical eye procedures |
| WO2008151179A2 (en) | 2007-06-04 | 2008-12-11 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
| CN101327216A (zh) | 2007-06-22 | 2008-12-24 | 肖正连 | 一种硫酸阿托品眼用即型凝胶 |
| JP5640207B2 (ja) * | 2007-10-08 | 2014-12-17 | セラオプティクスＴｈｅｒａｏｐｔｉｃｓ | 水性眼用処方物 |
| US7815605B2 (en) | 2007-11-28 | 2010-10-19 | Souter Steve R | Emergency medication pump injection system |
| CN101468214A (zh) * | 2007-12-27 | 2009-07-01 | 上海华捷视医疗设备有限公司 | 一种眼科手术用重水及其制备方法 |
| EP2508189A3 (de) | 2008-04-20 | 2012-11-07 | D2 Bioscience Group Ltd | Verwendung von Deuteriumoxid als Elastase-Inhibitor |
| AU2009325061B2 (en) | 2008-12-11 | 2014-05-29 | Children's Medical Center Corporation | Contact lens drug delivery device |
| DE102009003942A1 (de) | 2009-01-07 | 2010-07-08 | D2O Biosience Group Ltd., Hamilton | Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges |
| US8883214B2 (en) | 2009-01-13 | 2014-11-11 | The Regents Of The University Of California | Implantable delivery vehicle for ocular delivery of muscarinic antagonists |
| TW201043211A (en) | 2009-03-31 | 2010-12-16 | Johnson & Johnson Vision Care Inc | Punctal plugs |
| US20120203161A1 (en) * | 2009-08-12 | 2012-08-09 | Seros Medical, Llc | Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use |
| FR2950036B1 (fr) | 2009-09-11 | 2011-12-16 | Rexam Pharma La Verpilliere | Dispositif de distribution de liquide |
| FR2952040B1 (fr) | 2009-10-29 | 2011-12-30 | Rexam Pharma La Verpilliere | Dispositif de distribution de liquide sous forme de gouttes |
| WO2011098578A2 (en) | 2010-02-12 | 2011-08-18 | Bioneer A/S | Liposome system for ocular administration |
| KR20130111932A (ko) * | 2010-04-30 | 2013-10-11 | 세로스 메디컬, 엘엘씨 | 조합 방식을 이용하여 안구 조직을 치료하는 방법 및 장치 |
| TWI424663B (zh) | 2010-07-01 | 2014-01-21 | Joy Ride Tech Co Ltd | A motor with heat pipe |
| AU2011278934B2 (en) | 2010-07-15 | 2015-02-26 | Eyenovia, Inc. | Drop generating device |
| MX2013000604A (es) | 2010-07-15 | 2013-07-05 | Corinthian Ophthalmic Inc | Suministro oftálmico de fármaco. |
| TW201217533A (en) | 2010-08-04 | 2012-05-01 | Bayer Pharma AG | Genomics of actinoplanes utahensis |
| WO2012111029A2 (en) * | 2011-02-18 | 2012-08-23 | M/S. Appasamy Associates | Ophthalmic composition for enabling dilation of pupils |
| CN103501764A (zh) | 2011-03-03 | 2014-01-08 | 阿勒根公司 | 基于硅酮的眼科制剂 |
| EP3799866A1 (en) | 2011-04-05 | 2021-04-07 | Optosolve Research & Development Ltd | Ophthalmic treatments comprising tramadol |
| AU2012253335B2 (en) | 2011-05-12 | 2016-08-04 | Takeda Pharmaceutical Company Limited | Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories |
| WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| TW201302244A (zh) | 2011-07-08 | 2013-01-16 | Univ Nat Chiao Tung | 載藥型隱形眼鏡及其製備方法 |
| WO2013079580A1 (en) | 2011-11-29 | 2013-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of darier disease |
| US20170304152A1 (en) | 2012-02-01 | 2017-10-26 | Certa Dose, Inc. | Apparatuses, methods, and systems for delivering medication using medication kits |
| US9814729B2 (en) | 2012-03-14 | 2017-11-14 | The Regents Of The University Of California | Nerve agent antidotes |
| EP2844295A1 (en) | 2012-05-03 | 2015-03-11 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| KR20150028241A (ko) | 2012-05-11 | 2015-03-13 | 시플라 리미티드 | 약학적 조성물 |
| CN104602653B (zh) | 2012-05-14 | 2018-02-16 | 艾诺维亚股份有限公司 | 层流液滴发生器装置以及使用方法 |
| BR112014028400A2 (pt) | 2012-05-15 | 2018-04-24 | Eyenovia Inc | dispositivos ejetores, métodos, acionadores e circuitos para os mesmos |
| US20150297800A1 (en) | 2012-07-03 | 2015-10-22 | Sio2 Medical Products, Inc. | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS |
| US9827250B2 (en) | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| MX361858B (es) | 2012-08-24 | 2018-12-18 | Sun Pharma Global Fze | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. |
| US9498035B2 (en) | 2012-12-21 | 2016-11-22 | Coopervision International Holding Company, Lp | Silicone hydrogel contact lenses for sustained release of beneficial polymers |
| WO2014140105A1 (en) | 2013-03-13 | 2014-09-18 | D2 Bioscience Group Ltd. | Materials and compositions for dental cements and filler materials |
| US20160018671A1 (en) | 2013-03-29 | 2016-01-21 | Onefocus Technology, Llc | Drug delivery from contact lenses with a fluidic module |
| KR102027663B1 (ko) | 2013-05-06 | 2019-10-01 | 가오슝 창 궁 메모리얼 하스피털 | 약학적 조성물 및 이의 용도 |
| SG10201709469SA (en) | 2013-05-17 | 2017-12-28 | Incyte Corp | Bipyrazole derivatives as jak inhibitors |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| DE102013218802B4 (de) | 2013-09-19 | 2018-06-28 | Aero Pump Gmbh | Abgabevorrichtung für Fluide aus einem Fluidbehälter |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US20160009705A1 (en) | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US10123904B2 (en) | 2014-08-13 | 2018-11-13 | University Of Florida Research Foundation, Inc. | Preservative removal from eye drops |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| DE102015104646B3 (de) | 2015-03-26 | 2016-06-30 | Aero Pump Gmbh | Abgabevorrichtung für ein Fluid |
| CN107847432A (zh) | 2015-05-29 | 2018-03-27 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| ES2929368T3 (es) | 2016-05-25 | 2022-11-28 | Singapore Health Serv Pte Ltd | Composición acuosa que contiene atropina |
| CN109689027A (zh) | 2016-06-29 | 2019-04-26 | 奥德纳米有限公司 | 甘油三酯耳用制剂及其用途 |
| AU2017328907B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| NZ756936A (en) | 2017-02-21 | 2022-11-25 | Singapore Health Serv Pte Ltd | Composition and method for preventing or delaying onset of myopia comprising atropine |
| SG11201910085UA (en) | 2017-05-11 | 2019-11-28 | Nevakar Inc | Atropine pharmaceutical compositions |
| AU2018304450B2 (en) | 2017-07-20 | 2024-05-16 | Seinda Pharmaceutical Guangzhou Corporation | Composition and methods for the treatment of myopia |
| MX2020005217A (es) | 2017-11-21 | 2020-11-24 | Sydnexis Inc | Composicion oftalmica y dispositivo de administracion de la misma. |
| IL293859A (en) | 2019-12-16 | 2022-08-01 | Sydnexis Inc | Ophthalmic preparations that include d2o |
-
2015
- 2015-05-29 US US14/726,139 patent/US9421199B2/en active Active
- 2015-06-23 WO PCT/US2015/037249 patent/WO2015200361A1/en active Application Filing
- 2015-06-23 JP JP2016574898A patent/JP6678362B2/ja active Active
- 2015-06-23 EP EP20159621.0A patent/EP3689350A1/en active Pending
- 2015-06-23 KR KR1020177002056A patent/KR102506109B1/ko active IP Right Grant
- 2015-06-23 RS RS20220765A patent/RS63486B1/sr unknown
- 2015-06-23 PL PL15811865.3T patent/PL3160471T3/pl unknown
- 2015-06-23 KR KR1020217029081A patent/KR102710491B1/ko active IP Right Grant
- 2015-06-23 SG SG10201913976SA patent/SG10201913976SA/en unknown
- 2015-06-23 KR KR1020247031630A patent/KR20240144477A/ko active Search and Examination
- 2015-06-23 SG SG10201707617VA patent/SG10201707617VA/en unknown
- 2015-06-23 CN CN201910968378.3A patent/CN110638749A/zh active Pending
- 2015-06-23 KR KR1020197038476A patent/KR20200001612A/ko not_active IP Right Cessation
- 2015-06-23 DK DK15811865.3T patent/DK3160471T3/da active
- 2015-06-23 BR BR112016030368-7A patent/BR112016030368B1/pt active IP Right Grant
- 2015-06-23 PT PT158118653T patent/PT3160471T/pt unknown
- 2015-06-23 SI SI201531871T patent/SI3160471T1/sl unknown
- 2015-06-23 ES ES15811865T patent/ES2924243T3/es active Active
- 2015-06-23 CN CN201580045735.9A patent/CN106572998B/zh active Active
- 2015-06-23 CA CA2953363A patent/CA2953363C/en active Active
- 2015-06-23 EP EP15811865.3A patent/EP3160471B1/en active Active
- 2015-06-23 LT LTEPPCT/US2015/037249T patent/LT3160471T/lt unknown
- 2015-06-23 SG SG11201610682UA patent/SG11201610682UA/en unknown
- 2015-06-23 HR HRP20220972TT patent/HRP20220972T1/hr unknown
- 2015-06-23 CN CN202210803133.7A patent/CN115192520A/zh active Pending
- 2015-06-23 EP EP22175801.4A patent/EP4115884A1/en active Pending
- 2015-06-23 HU HUE15811865A patent/HUE059521T2/hu unknown
- 2015-06-24 TW TW104120379A patent/TWI763620B/zh active
- 2015-06-24 TW TW112131152A patent/TW202412797A/zh unknown
-
2016
- 2016-04-25 US US15/568,381 patent/US10842787B2/en active Active
- 2016-07-12 US US15/208,537 patent/US9770447B2/en active Active
- 2016-12-19 IL IL249643A patent/IL249643B/en unknown
-
2017
- 2017-07-27 US US15/661,816 patent/US10076515B2/en active Active
-
2018
- 2018-02-13 US US15/895,933 patent/US10201534B2/en active Active
- 2018-12-18 US US16/224,286 patent/US10864208B2/en active Active
-
2020
- 2020-01-30 JP JP2020014108A patent/JP7505888B2/ja active Active
- 2020-11-13 US US17/097,930 patent/US11596625B2/en active Active
-
2022
- 2022-01-12 JP JP2022003408A patent/JP2022062045A/ja active Pending
- 2022-11-16 US US18/055,949 patent/US11883390B2/en active Active
- 2022-11-16 US US18/055,945 patent/US11896588B2/en active Active
- 2022-11-16 US US18/055,940 patent/US11890277B2/en active Active
-
2023
- 2023-10-19 JP JP2023180519A patent/JP2024050526A/ja active Pending
- 2023-12-14 US US18/539,823 patent/US20240165098A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220972T1 (hr) | Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu | |
| HRP20191667T1 (hr) | Vodenasta oftalmološka otopina i postupak tretmana sindroma suhog oka | |
| JP2022062045A5 (hr) | ||
| HRP20220762T1 (hr) | Upotreba pilokarpin-hidroklorida u liječenju prezbiopije | |
| JP2018521000A5 (hr) | ||
| JP2017522292A5 (hr) | ||
| MX2014001101A (es) | Composiciones orales que contienen un ester 17-hydroxyprogesterona y metodos relacionados. | |
| HRP20192266T1 (hr) | Kompozicije i postupci za nekirurško liječenje ptoze | |
| MX2017016823A (es) | Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados. | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| RU2012101782A (ru) | Водные фармацевтические композиции, содержащие комплексы боратполиол | |
| JP2011527709A5 (hr) | ||
| KR20190013877A (ko) | 아트로핀-함유 수성 조성물 | |
| HRP20211515T1 (hr) | Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni | |
| WO2007108541A1 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
| RU2013129222A (ru) | Глазные композиции, содержащие мукоадгезивные полисахариды, способные стимулировать восстановление эпителия роговицы | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| RU2014103544A (ru) | Комбинация фиксированных доз биматопроста и бримонидина | |
| TW202031263A (zh) | 抑制軟性隱形眼鏡變質之眼科用組成物 | |
| JP2016503058A5 (hr) | ||
| HRP20161717T1 (hr) | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama | |
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
| ES2899759T3 (es) | Composición hiperosmolar de ácido hialurónico | |
| AR106691A1 (es) | Formulaciones oftálmicas de escualamina | |
| JP6449774B2 (ja) | 両性イオン性ソフトコンタクトレンズ用眼科用組成物 |